We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 09, 2021

Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With HER2+ Metastatic Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
A Phase II Study of Efficacy, Toxicity, and the Potential Impact of Genomic Alterations on Response to Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Human Epidermal Growth Factor Receptor 2 (HER2)+ Metastatic Breast Cancer
Breast Cancer Res Treat 2021 Jul 24;[EPub Ahead of Print], SM Balch, I Vaz-Luis, T Li, N Tayob, E Jain, K Helvie, JE Buendia-Buendia, E Shannon, SJ Isakoff, NM Tung, IE Krop, NU Lin, N Wagle, RA Freedman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading